

## UNTIL SHE FORGETS WHY SHE CAME TO SEE YOU AGAIN

A GUIDE TO MILD COGNITIVE IMPAIRMENT FOR HEALTHCARE PRACTITIONERS.


### THE DISORDER THAT EVERYONE SHOULD BE TALKING ABOUT: MILD COGNITIVE IMPAIRMENT

Mild cognitive impairment (MCI) is a condition prodromal to Alzheimer's disease.<sup>1</sup>

It is characterised by a subjective memory impairment and modest deficits in at least one of five main cognitive domains<sup>1</sup>:

- executive function
- memory
- language
- processing speed
- attention

The prevalence of MCI is estimated to range from 12-21% for individuals aged 65+. This could be an underestimate due to underdiagnoses.<sup>2-6</sup>




## THE INS & OUTS OF MILD COGNITIVE IMPAIRMENT

This graph highlights the effect of brain energy rescue.

The increase of brain energy helps counter the effects of MCI and the progression to Alzheimer's disease by helping to close the brain energy gap, ultimately improving cognitive performance in MCI patients.<sup>1</sup>







### IS THERE A CLINICALLY-PROVEN ORAL NUTRITIONAL SUPPLEMENT TO SUPPORT PATIENTS?

### THE SHORT ANSWER: YES, BRAINXPERT ENERGY COMPLEX



BrainXpert Energy Complex is a breakthrough innovation made of encapsulated Medium-Chain Triglycerides (MCT) mixed with protein, which is proven to have a positive effect on memory and cognitive functions.<sup>16</sup>

## WHAT IS THE CLINICAL EVIDENCE BEHIND BRAINXPERT?

In recent studies,<sup>16,17</sup> an intervention with an Oral Nutritional Supplement containing ketogenic Medium-Chain Triglycerides, has proven not only to improve cognitive performance but also improve energy conversion in the brain by PET both before and after a 6-month intervention in mild cognitive impairment patients.



### WHAT WAS THE OUTCOME OF THE STUDY?

An Oral Nutritional Supplement providing 30g of ketogenic Medium-Chain Triglycerides daily for six months had the following results:


• Ketone PET imaging showed increased brain ketone uptake in MCI patients.

• Similar blood ketone response in MCI patients.

• 4 cognitive tests showed a statistically significant improvement: Free and Cued Recall (p = 0.047), Verbal Fluency (p= 0.024), Boston Naming Test (p= 0.033) and Trail Making Test (P = 0.017).

- Improvement of scores in 3 of the 5 main cognitive domains (Episodic Memory, Executive Function & Language).
- Higher plasma and brain ketones correlated positively with changes in 4 cognitive tests.
- Good efficacy, safety, compliance & tolerability.

### IN CONCLUSION, THE ORAL NUTRITIONAL SUPPLEMENT:



• Improved cognitive outcomes in MCI patients as the increased availability of ketones significantly improved brain energy supply. This includes clinical proof of improving memory, word recall, thinking speed and multitasking.

• Proved it is safe and feasible for an MCI population to comply with an intervention of 15g Medium-Chain Triglyceride Oral Nutritional Supplement twice daily for 6 months.

\* Randomized placebo control study. Active intervention= 39, Placebo n=43.

\*\* 15g kMCT-ONS with milk protein per serving. Placebo: non-ketogenic ONS equivalent formulation.

## HOW DOES BRAINXPERT WORK?

BrainXpert is a Food for Special Medical Purposes to be used under medical supervision that was designed to compensate for the impairment in brain energy metabolism in mild cognitive impairment patients.

It contains encapsulated MCTs that are metabolised by the liver to ketones and then utilised as an alternative source of energy in the brain. In addition, the product contains a vitamin complex (B6, B12 and folic acid), which is specifically designed to meet the requirements of patients with MCI in order to decrease levels of homocysteine in the brain.



# WHAT ARE THE CONSUMPTION RECOMMENDATIONS?

BrainXpert should be used for the dietary management of patients with mild cognitive impairment.

### **DIRECTIONS FOR USE**

Patients should take two servings per day, morning and afternoon, within a meal occasion.



Stir until dissolved and start enjoying the benefits

# WHAT IS THE NUTRITIONAL INFORMATION?

BrainXpert includes:

Encapsulated MCT (medium chain triglycerides, glucose syrup, **milk protein**, potassium phosphate, calcium phosphate), **milk protein**, vitamin mix (B6, B9, B12).

## No preservatives No artificial flavours

## No artificial sweeteners No artificial colours

Nutrition Information			
		Per 100 g	Per 25 g Sachet
Energy	kJ / kcal	2818 / 681	705 / 170
Fat	g	60	15
Saturates	g	60	15
Medium Chai Triglycerides		60	15
Carbohydrate	e g	20	5.0
Sugars	g	2.8	0.70
Lactose	g	< 0.1	-
Protein	g	15.2	3.8
Salt	g	0.71	0_18
MINERALS			
Sodium	mg / mmol	284 / 12.4	71 / 3.1
Potassium	mg / mmol	536 / 13.7	134 / 3.4
Calcium	mg / mmol	312 / 7.8	7.8 / 0.2
Phosphorus	mg	520	130
Phosphates	mmol	16.8	4.2
VITAMINS			·
Vitamin B6	mg	40	10
Folic Acid	μg	1,600	400
Vitamin B12	μg	1,000	250





### HOW CAN YOU SUPPORT PATIENTS WITH MILD COGNITIVE IMPAIRMENT?<sup>19,20</sup>

#### KEEP THIS PAGE AND PIN IT UP TO HELP YOU REMEMBER.

Patient's concern regarding changes in memory, language, visuospatial function and/or attention/executive function.

History results focused on the following return positive results: changes in cognitive function and functional status, polypharmacy, neurological and psychiatric symptoms.

Physical and neurological exam and laboratory testing return positive results.

Cognitive testing and brain imaging techniques return positive results. Evaluate risk factors that are potentially modifiable.

Consider multi-domain interventions such as **BrainXpert** (we would recommend to follow a titration protocol for the first two weeks of product consumption for a better tolerability). Also consider: Optimise vascular risk factor control; Treat comorbidities if present; Review medication that negatively affects cognitive function; Optimise vision, hearing,


sleep disordered breathing; Recommend regular exercise (twice/week) and cognitive interventions; Counsel patient & family on beneficial behaviours, safety, finances, long-term care and prognosis; Extra energy source to compensate glucose deficiency.

Follow up every 6 months.

ALL YOU NEED TO REMEMBER

If any of the stages have a negative result, it is still recommended to follow up every 6 months to assess changes in cognitive function.

BRAINXPERT



BRAINXPERT ALL YOU NEED TO REMEMBER

#### REFERENCES

1- Cunnane, S.C., et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov 2020. https://doi.org/10.1038/s41573-020-0072-x 2- Hu, C., et al. The prevalence and progression of mild cognitive impairment among clinic and community populations: a systematic review and meta-analysis. Int Psychogeriatr 2017;29(10): 1595-1608. 3- Pessoa, R. M. P., et al. Diagnostic criteria and prevalence of mild cognitive impairment in older adults living in the community: a systematic review and meta-analysis. Archives of Clinical Psychiatry 2019;46: 72-79. 4- Petersen, R. C. Mild Cognitive Impairment, Continuum (Minneap Minn) 2016; 22(2 Dementia):404-18. 5- Vancampfort, D., B., et al. Mild cognitive impairment and physical activity in the general population: Findings from six low- and middle-income countries. Exp Gerontol 2017: 100: 100-105.

6- Xue, J., et al. The Prevalence of Mild Cognitive Impairment in China: A Systematic Review. Aging Dis 2018; 9(4): 706-715. 7- Canevelli, M., G., et al. Spontaneous Reversion of Mild Cognitive Impairment to Normal Cognition: A Systematic Review of Literature and Meta-Analysis. J Am Med Dir Assoc 2016:17(10) 943-948. 8- Koepsell, T. D, et al. Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis. Neurology 2012; 79(15):1591-1598. 9- Malek-Ahmadi, M. Reversion From Mild Cognitive Impairment to Normal Cognition: A Meta-Analysis. Alzheimer Dis Assoc Disord 2016; 30(4): 324-330. 10- Manly, J. J., et al. Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol 2008; 63(4) 494-506 11- Roberts, R., et al. Higher risk of progression to dementia

in mild cognitive impairment cases who revert to normal. Neurology 2014; 82(4):317-325.

12- Arevalo-Rodriguez, I., N., et al. Mini-Mental State Examination (IMMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2015:(3) CD010783.

**13**- Han, J. W., et al. Predictive validity and diagnostic stability of mild cognitive impairment subtypes. Alzheimers Dement 2012;8(6):553-559.

14- Nugent, S., A. et al. Ketones and brain development: Implications for correcting deteriorating brain glucose metabolism during aging. OCL 2016; 23(1): D110.
15- Castellano, C. A., et al. Links Between Metabolic and Structural Changes in the Brain of Cognitively Normal Older Adults: A 4-Year Longitudinal Follow-Up. Frontiers in aging neuroscience 2019; 11: 15.

16- Fortier, M., et al. A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment Alzheimer's & Dementia 15 (2019) 625-634.
17- Henderson, S. Ketosis in Mild Cognitive Impairment and Alzheimer's Disease 2015: 447-456.

18- Avgerinos, K. I., J., et al. Medium Chain Triglycerides induce mild ketosis and may improve cognition in Alzheimer's disease. A systematic review and meta-analysis of human studies. Ageing Res Rev 2019; 58:101001. 19- Langa, K. et al. The Diagnosis and Management of Mild

Cognitive Impairment: A Clinical Review. JAMA 2014; 312(23): 2551–2561.

20- Petersen, R. et al. Practice guideline update summary: Mild cognitive impairment. Neurology 2018;90:126-135.
21- Fortier, M., et al. A ketogenic drink improves cognition in Mild Cognitive Impairment: results of a 6-month RCT In press Alzheimer's & Dementia 2020.

MORE FOOD FOR THOUGHT AT www.nestlehealthscience.com/brainXpert

Communication to Healthcare Professionals only (September 2020). Use product under medical supervision. Not suitable as a sole source of nutrition. Not for intravenous use. Only suitable for adults.